Overview

Study In People With Type 2 Diabetes

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Pioglitazone